Increasing occurrence of ovarian cancer is expected to drive the growth of global ovarian cancer drugs market in the forecast period, 2023-2027.
According to TechSci Research report, “Ovarian Cancer Drugs Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027”, the global ovarian cancer drugs market is anticipated to grow at an impressive rate during the forecast period, 2023-2027. This can be ascribed to the growing incidence of ovarian cancer worldwide. According to global cancer observatory, around 313,959 new cases of ovarian cancer were reported worldwide in 2020, with 207,252 reported deaths. This has in turn increased the demand for different drugs required for the treatment of ovarian cancer, thereby driving the market growth. Additionally, patent expiry of several leading drugs used in the treatment of ovarian cancer is expected to create lucrative opportunities for the market growth by creating room for the entry of generic drugs manufacturers in the space. Furthermore, continuous research & development to produce efficient therapeutic intervention for numerous diseases boost the ovarian cancer drugs market. Many drugs are in different phases of clinical trials and can be expected soon in the market.
However, it is most likely anticipated that the lack of accurate early-stage diagnostic tools for ovarian cancer will further restrain the market for ovarian cancer drugs in the years to come. Additionally, stringent regulatory scenario in terms of drug application fillings and approvals is expected to slow down the market growth in the coming years.
Browse over XX market data Figures spread through 110 Pages and an in-depth TOC on “OVARIAN CANCER DRUGS MARKET“
The global ovarian cancer drugs market is segmented into by drug class, by tumor type, by distribution channel and by region.
Based on tumor type, the ovarian cancer drugs market can be categorized into epithelial ovarian cancer, ovarian low malignant potential tumor, germ cell tumor and sex cord-stromal tumor. The epithelial ovarian cancer segment is expected to dominate the market during the forecast period. This can be ascribed to the fact that this is the most commonly observed ovarian cancer type worldwide. Around 90% of ovarian tumors are epithelial.
Based on distribution channel, the global ovarian cancer drugs market can be segmented hospital pharmacies, retail pharmacies and online pharmacies. The hospital pharmacies segment dominated the market in 2021 on account of easy availability of different ovarian cancer drugs in the hospital pharmacies.
Based on region, because of the rising ovarian cancer incidences, North America currently dominates the ovarian cancer drug market. The expansion of the ovarian cancer drugs market in the region will also be aided by the introduction of new products, increased adoption of novel therapies, and a sizable target population throughout the forecast period.
Major operating companies operating in global ovarian cancer drugs market are:
- AstraZeneca, Plc.
- GlaxoSmithKline, Plc.
- Merck & Co.
- Clovis Oncology, Inc.
- F. Hoffmann-La Roche AG
- Bristol-Myers Squibb Co.
- Eli Lilly and Company
- Amgen Inc.
- C.H. Boehringer Sohn Ko. KG
- Novartis AG
Customers can also request for 10% free customization on this report.
“Asia Pacific region is expected to register the highest growth in global ovarian cancer drugs market during the forecast period on account of growing incidence of the cancer especially in countries like China, India, Japan, among others. Additionally, increasing drug development and discovery related to ovarian cancer drugs and increasing number of clinical trials launched for the development of ovarian cancer drugs especially in countries like China and India is expected to create lucrative opportunities for the market growth through 2027.” said Mr. Karan Chechi, Research Director with TechSci Research, a research based global management consulting firm.
“Ovarian Cancer Drugs Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Drug Class (Alkylating Agents, Mitotic Inhibitors, Antirheumatics, Antipsoriatics, VEGF/VEGFR Inhibitors, PARP Inhibitors, Antineoplastics, Others), By Tumor Type ( Epithelial Ovarian Cancer, Ovarian Low Malignant Potential Tumor, Germ Cell Tumor, Sex Cord-Stromal Tumor), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and By Region”, has evaluated the future growth potential of global ovarian cancer drugs market and provides statistics & information on market size, structure, and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in global ovarian cancer drugs market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: https://www.techsciresearch.com